In a report released today, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Ascendis Pharma (ASND – Research Report). The company’s shares closed yesterday at $124.28.
Ahmad covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Ascendis Pharma, and Ultragenyx Pharmaceutical. According to TipRanks, Ahmad has an average return of 3.2% and a 50.45% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Ascendis Pharma with a $192.85 average price target, representing a 55.17% upside. In a report released today, TD Cowen also assigned a Buy rating to the stock with a $153.00 price target.
ASND market cap is currently $7.13B and has a P/E ratio of -13.31.
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Ascendis Pharma (ASND) Company Description:
Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. Through its TransCon technology, it develops a pipeline of sustained release prodrug therapies including endocrinology product candidates to support the market. The company was founded by Jan Moller Mikkelsen and Harald Rau in September 2006 and is headquartered in Hellerup, Denmark.
Read More on ASND:
- Ascendis Pharma price target raised to $207 from $200 at Stifel
- Ascendis Pharma price target lowered to $153 from $160 at TD Cowen
- Ascendis Pharma Reports Strong Q3 2024 Results
- Closing Bell Movers: Applied Materials down 6% after earnings, guidance
- Ascendis Pharma Reports Revenue Growth Despite Loss
